Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis.
作者信息
Krueger James G, Murrell Dedee F, Garcet Sandra, Navrazhina Kristina, Lee Patricia C, Muscianisi Elisa, Blauvelt Andrew
机构信息
Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY.
Department of Dermatology, St George Hospital, University of New South Wales, Sydney, Australia.
出版信息
J Allergy Clin Immunol. 2021 Mar;147(3):1107-1109.e2. doi: 10.1016/j.jaci.2020.09.021. Epub 2020 Sep 28.
Abstract
摘要
相似文献
1
Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis.
J Allergy Clin Immunol. 2021 Mar;147(3):1107-1109.e2. doi: 10.1016/j.jaci.2020.09.021. Epub 2020 Sep 28.
2
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23.
3
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
Lancet. 2021 Apr 24;397(10284):1564-1575. doi: 10.1016/S0140-6736(21)00440-2.
4
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
J Allergy Clin Immunol. 2019 Sep;144(3):750-763. doi: 10.1016/j.jaci.2019.04.029. Epub 2019 May 24.
5
Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab.
J Dermatol. 2019 Dec;46(12):e468-e469. doi: 10.1111/1346-8138.15082. Epub 2019 Sep 9.
6
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.
Clin Pharmacol Ther. 2019 Dec;106(6):1380-1388. doi: 10.1002/cpt.1558. Epub 2019 Aug 3.
7
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
J Dermatol. 2019 Sep;46(9):752-758. doi: 10.1111/1346-8138.15004. Epub 2019 Jul 25.
8
A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report.
Curr Drug Saf. 2020;15(1):69-72. doi: 10.2174/1574886314666190726155147.
9
Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.
J Dermatol. 2017 Oct;44(10):1129-1137. doi: 10.1111/1346-8138.13900. Epub 2017 May 11.
10
Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.
Gastroenterology. 2021 Feb;160(3):809-822.e7. doi: 10.1053/j.gastro.2020.10.041. Epub 2020 Nov 5.
引用本文的文献
1
Biologics protect psoriasis patients from being exacerbated by COVID-19 infection.
Heliyon. 2024 Jan 14;10(2):e24534. doi: 10.1016/j.heliyon.2024.e24534. eCollection 2024 Jan 30.
2
Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database.
Sci Rep. 2024 Jan 12;14(1):1222. doi: 10.1038/s41598-023-50013-7.
3
Bibliometric analysis and description of research trends on T cells in psoriasis over the past two decades (2003-2022).
Heliyon. 2023 Dec 10;10(1):e23542. doi: 10.1016/j.heliyon.2023.e23542. eCollection 2024 Jan 15.
4
The Renin-Angiotensin System: The Challenge behind Autoimmune Dermatological Diseases.
Diagnostics (Basel). 2023 Nov 7;13(22):3398. doi: 10.3390/diagnostics13223398.
5
Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics.
Expert Rev Clin Immunol. 2022 Sep;18(9):947-960. doi: 10.1080/1744666X.2022.2105697. Epub 2022 Jul 28.
6
IL-33 Enhances ACE2 Expression on Epidermal Keratinocytes in Atopic Dermatitis: A Plausible Issue for SARS-CoV-2 Transmission in Inflamed Atopic Skin.
Biomedicines. 2022 May 20;10(5):1183. doi: 10.3390/biomedicines10051183.
7
Biologics for Psoriasis During the COVID-19 Pandemic.
Front Med (Lausanne). 2021 Dec 6;8:759568. doi: 10.3389/fmed.2021.759568. eCollection 2021.
8
Skin Aging, Cellular Senescence and Natural Polyphenols.
Int J Mol Sci. 2021 Nov 23;22(23):12641. doi: 10.3390/ijms222312641.
9
Switching infliximab in psoriatic patients during COVID-19 pandemics: A real-life retrospective study comparing intra-versus interclass switching strategies.
Dermatol Ther. 2021 Sep;34(5):e15088. doi: 10.1111/dth.15088. Epub 2021 Aug 16.
10
A Working Hypothesis on Vesicular Lesions Related to COVID-19 Infection, Koebner Phenomena Type V, and a Short Review of Related Data.
Clin Cosmet Investig Dermatol. 2021 Apr 30;14:419-423. doi: 10.2147/CCID.S307846. eCollection 2021.
Zotero 插件